Specialty pharmacy Diplomat Pharmacy has announced that it will stock Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets), which was approved Dec. 19 by the Food and Drug Administration.
Specialty Pharmacy News
The Food and Drug Administration granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.
The overwhelming majority of GlaxoSmithKline shareholders on Thursday approved the proposed transaction with Novartis.
McKesson Specialty Health on Wednesday announced that its Reimbursement, Access & Safety Services Solution Center has earned certification by BenchmarkPortal as a Center of Excellence for the sixth consecutive year.
Ipsen Biopharmaceuticals on Tuesday announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors.
Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use.
Diplomat announced a new partnership with Novation through their Hospital Specialty Rx Program on Thursday.
Mylan on Thursday announced that its subsidiary, Mylan Labs, was granted tentative approval from the Food and Drug Administration for two dosages of abacavir/lamivudine tablets for oral suspension.
Diplomat Pharmacy announced Wednesday that it has been selected to Pfizer's limited-distribution panel for Xalkori, Bosulif, Inlyta and Sutent.
Ranbaxy Laboratories on Monday announced the launch of Infimab (BOW015), the first Remicade (Infliximab) biosimilar in India. The product was launched at the Indian Rheumatology Association Conference in Chandigarh.